Taigen Biopharmaceutica Valuation
| 4157 Stock | TWD 11.45 0.35 2.97% |
At this time, the company appears to be overvalued. Taigen Biopharmaceutica has a current Real Value of NT$10.38 per share. The regular price of the company is NT$11.45. Our model measures the value of Taigen Biopharmaceutica from inspecting the company fundamentals such as Return On Equity of -0.21, current valuation of 11.41 B, and Shares Owned By Insiders of 35.93 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Taigen Biopharmaceutica's price fluctuation is not too volatile at this time. Calculation of the real value of Taigen Biopharmaceutica is based on 3 months time horizon. Increasing Taigen Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Taigen stock is determined by what a typical buyer is willing to pay for full or partial control of Taigen Biopharmaceuticals Holdings. Since Taigen Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Taigen Stock. However, Taigen Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.45 | Real 10.38 | Hype 11.45 | Naive 11.58 |
The intrinsic value of Taigen Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Taigen Biopharmaceutica's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Taigen Biopharmaceuticals Holdings helps investors to forecast how Taigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Taigen Biopharmaceutica more accurately as focusing exclusively on Taigen Biopharmaceutica's fundamentals will not take into account other important factors: Taigen Biopharmaceutica Total Value Analysis
Taigen Biopharmaceuticals Holdings is presently anticipated to have takeover price of 11.41 B with market capitalization of 11.33 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Taigen Biopharmaceutica fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
11.41 B | 11.33 B |
Taigen Biopharmaceutica Investor Information
About 36.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Based on the key measurements obtained from Taigen Biopharmaceutica's financial statements, Taigen Biopharmaceuticals Holdings is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Taigen Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Taigen Biopharmaceutica has an asset utilization ratio of 92.94 percent. This indicates that the Company is making NT$0.93 for each dollar of assets. An increasing asset utilization means that Taigen Biopharmaceuticals Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Taigen Biopharmaceutica Ownership Allocation
Taigen Biopharmaceutica shows a total of 716.84 Million outstanding shares. Taigen Biopharmaceutica maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Taigen Biopharmaceutica Profitability Analysis
The company reported the revenue of 1.29 B. Net Income was 775.62 M with profit before overhead, payroll, taxes, and interest of 1.28 B.About Taigen Biopharmaceutica Valuation
Our relative valuation model uses a comparative analysis of Taigen Biopharmaceutica. We calculate exposure to Taigen Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Taigen Biopharmaceutica's related companies.8 Steps to conduct Taigen Biopharmaceutica's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Taigen Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Taigen Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Taigen Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Taigen Biopharmaceutica's revenue streams: Identify Taigen Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Taigen Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Taigen Biopharmaceutica's growth potential: Evaluate Taigen Biopharmaceutica's management, business model, and growth potential.
- Determine Taigen Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Taigen Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Taigen Stock Analysis
When running Taigen Biopharmaceutica's price analysis, check to measure Taigen Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taigen Biopharmaceutica is operating at the current time. Most of Taigen Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Taigen Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taigen Biopharmaceutica's price. Additionally, you may evaluate how the addition of Taigen Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.